Drug Profile
Resminostat - 4SC
Alternative Names: 4SC-201; BYK-408740; Kinselby; RAS-2410; Resminostat-4-SC; YHI-1001Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Nycomed
- Developer 4SC; Yakult Honsha
- Class Antineoplastics; Dimethylamines; Hydroxylamines; Pyrroles; Small molecules; Sulfonamides
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Biliary cancer; Cutaneous T-cell lymphoma; Hodgkin's disease; Liver cancer; Mycosis fungoides; Non-small cell lung cancer; Pancreatic cancer; Sezary syndrome
- Phase I/II Colorectal cancer
- No development reported Solid tumours
- Discontinued Diffuse large B cell lymphoma
Most Recent Events
- 22 Mar 2024 4SC announces intention for submitting filings in the UK and Switzerland in cutaneous T-cell lymphoma
- 20 Dec 2023 4SC announces its intention to launch resminostat for the treatment of Cutaneous T-cell lymphoma in the Europe
- 19 Oct 2023 4SC announces its intention to file for Marketing Approval for Cutaneous T-cell lymphoma (PO) in Switzerland and the United Kingdom